Trevi Therapeutics logo

Trevi Therapeutics

TRVI | NASDAQ
Chart Builder DCF Calculator
$13.29
-$0.36 (-2.64%)
At close: Nov 16, 2026, 4:00 PM ET
$13.29
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:38 PM ET
-2.64%

Rating

Updated: Nov 16, 2026
18.1
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #1003/1021 (Top 98%)

Key Statistics

Market Data

Market Cap $2.12B
1D Range
13.15 13.67
52W Range
9.99 19.50

Valuation (TTM)

PE -34.08
PB 7.01
EV/EBITDA -30.05

Valuation (NTM)

Forward PE N/A
Forward PEG -1.02
Price Target $25.00
Loading financial charts...

Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated condi...

Sector Healthcare
Industry Biotechnology
Employees 34
IPO Date May 7, 2019
Fiscal Year January - December

Latest News

Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript

7 days ago · seekingalpha.com

Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call

7 days ago · marketbeat.com

What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

7 days ago · globenewswire.com

Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026

14 days ago · globenewswire.com

Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference

21 days ago · globenewswire.com

Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting

1 month ago · globenewswire.com

Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

3 months ago · globenewswire.com

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform

3 months ago · seekingalpha.com

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Trevi Therapeutics Q2 Earnings Call Highlights

3 months ago · marketbeat.com

Trevi Therapeutics Q2 Earnings Call Highlights

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$25.00
Upside
+88.11%
Buy (11)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.